Zobrazeno 1 - 8
of 8
pro vyhledávání: '"J P Lalezari"'
Autor:
D. Busch, M. Jacobson, Geoffrey J. Yuen, G L Drusano, L Drew, J P Lalezari, C Fletcher, S. Follansbee, James D. Connor, E Capparelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 39:2350-2352
We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)-infected patients through the use of nonlinear mixed-effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be
Autor:
W L, Drew, J P, Lalezari
Publikováno v:
Current clinical topics in infectious diseases. 19
Autor:
J P, Lalezari
Publikováno v:
Advance for nurse practitioners. 5(4)
Autor:
S A, Spector, G F, McKinley, J P, Lalezari, T, Samo, R, Andruczk, S, Follansbee, P D, Sparti, D V, Havlir, G, Simpson, W, Buhles, R, Wong, M, Stempien
Publikováno v:
The New England journal of medicine. 334(23)
In the advanced stages of the acquired immunodeficiency syndrome (AIDS), cytomegalovirus (CMV) disease, particularly vision-damaging retinitis due to CMV is common. We evaluated prophylactic treatment with orally administered ganciclovir as a way to
Publikováno v:
Advances in experimental medicine and biology. 394
Autor:
W L, Drew, D, Ives, J P, Lalezari, C, Crumpacker, S E, Follansbee, S A, Spector, C A, Benson, D N, Friedberg, L, Hubbard, M J, Stempien
Publikováno v:
The New England journal of medicine. 333(10)
Cytomegalovirus retinitis, a sight-threatening infection associated with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would be an important advance.We compared oral with
Autor:
S A, Spector, D F, Busch, S, Follansbee, K, Squires, J P, Lalezari, M A, Jacobson, J D, Connor, D, Jung, A, Shadman, B, Mastre
Publikováno v:
The Journal of infectious diseases. 171(6)
A phase I/II study evaluated the pharmacokinetics, tolerability, and antiviral activity of oral ganciclovir in persons infected with human immunodeficiency virus (HIV). Oral bioavailability ranged from 2.6% to 7.3%. The mean maximum serum concentrati
Autor:
B. Mastre, W. Buhles, J P Lalezari, D. Busch, R C Miner, M. Jacobson, S. Follansbee, W. Dankner, Stephen A. Spector, W L Drew
Publikováno v:
Antiviral Research. 15:127